Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
21 mars 2022 08h00 HE
|
Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
17 nov. 2021 09h15 HE
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
29 oct. 2020 16h36 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
28 sept. 2020 08h45 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
Bombardier étend le soutien mondial à la clientèle par des capacités accrues de réparations structurelles
27 juil. 2020 10h19 HE
|
Bombardier Avions d’affaires
Les capacités accrues procurent aux clients un soutien inégalé et plus de raison de ramener leurs avions dans les centres de services de Bombardier Le Centre de réponse à la clientèle (CRC) de...
Bombardier Expands Worldwide Customer Support with Enhanced Structural Repair Capabilities
27 juil. 2020 10h19 HE
|
Bombardier Business Aircraft
Extended capabilities provide customers with unparalleled support and more reasons to bring their jets home to Bombardier Bombardier’s Customer Response Center (CRC) remains the single point of...
Never Too Young Survey Report Shows Young-Onset Colorectal Cancer Continues to be Overlooked in Exam Rooms
04 juin 2020 11h27 HE
|
Colorectal Cancer Alliance
Washington, D.C., June 04, 2020 (GLOBE NEWSWIRE) -- Today, during Young Survivors Week, national leading non-profit Colorectal Cancer Alliance released findings from its latest survey of young-onset...
Updated: Expert Stakeholder Panel Focuses on Colorectal Cancer Screening in the COVID-19 Era
15 mai 2020 15h27 HE
|
Colorectal Cancer Alliance
Washington, D.C., May 15, 2020 (GLOBE NEWSWIRE) -- COVID-19 has produced far-reaching and significant health impacts, including a drastic reduction in all cancer screenings. In response, national...
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
23 avr. 2020 07h30 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating...
Colorectal Cancer Alliance Opens Young-Onset Colorectal Cancer Survey
20 juin 2019 16h23 HE
|
Colorectal Cancer Alliance
Washington, D.C., June 20, 2019 (GLOBE NEWSWIRE) -- National nonprofit Colorectal Cancer Alliance is calling on allies to participate in its fourth annual survey of young-onset colorectal cancer...